ProKidney Corp. (NASDAQ: PROK) is a Healthcare company (Biotechnology) with a market capitalization of $370M. The Maz Rating grades it against the other companies in its sector.
ProKidney Corp.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.10, ProKidney Corp. trades at 479.4x sales. Over the last twelve months it generated about $771493 of revenue and a net loss of $201M. It runs a gross margin of -12872.9%, an operating margin of -24830.3% and a net margin of -13326.7%. It shows return on equity of 10.8%, return on invested capital of -104.3% and a free cash flow yield of -45.4%. On the balance sheet: a debt-to-equity ratio of -0.00 and a current ratio of 5.04. Over the past 52 weeks the share price ranged from $0.87 to $2.65, with a beta of 1.90.
ProKidney Corp. does not currently pay a dividend.
8 Wall Street analyst ratings cover the stock: 6 Buy, 1 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.